Abbott Laboratories SEC filings, summarized
We read every Abbott Laboratories 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track ABT in your inbox
Add Abbott Laboratories to your watchlist — free, every morning.
Recent filings
Abbott CEO Robert Ford sells $46.2M in stock
Robert B. Ford, Abbott Laboratories’ chairman and CEO and a director, sold 218,535 shares at $115.57 each for about $25.3 million, leaving him with 486,758…
Abbott Agrees to $670 Million Settlement in Preterm Formula Litigation
On August 20, 2026, Abbott agreed to pay approximately $670 million to resolve the Gill case and NEC claims involving about 2,000 additional infants, rather…
Abbott Agrees to Pay $670 Million to Resolve Preterm Formula Claims
Abbott said on August 20, 2026, that it reached agreements with three law firms to resolve the Gill case and claims involving about 2,000 other individuals…
Abbott (via Badger Merger Sub I) has an Agreement & Plan of Merger with Exact Sciences dated Nov 19, 2025…
Abbott (via Badger Merger Sub I) has an Agreement & Plan of Merger with Exact Sciences dated Nov 19, 2025 incorporated by reference in an 8‑K filed Mar 23,…
Abbott ($ABT) closed its acquisition of Exact Sciences ($EXAS) on Mar 23, 2026.
Abbott ($ABT) closed its acquisition of Exact Sciences ($EXAS) on Mar 23, 2026. Merger Sub merged into Exact; Exact is now a direct, wholly owned subsidiary…
Abbott filed an 8‑K (Item 9.01) on Mar 9, 2026 furnishing an indenture and note forms for debt: Floating…
Abbott filed an 8‑K (Item 9.01) on Mar 9, 2026 furnishing an indenture and note forms for debt: Floating Rate due 2029; 3.70% (2029); 4.00% (2031); 4.30%…
Abbott Labs 8‑K filed 2026‑03‑09: Item 2.03 simply incorporates Item 1.01 by reference — it does not…
Abbott Labs 8‑K filed 2026‑03‑09: Item 2.03 simply incorporates Item 1.01 by reference — it does not itself create any new direct financial obligation or…
BREAKING: Abbott completes $20B senior notes offering to fund the Exact Sciences takeover — $ABT $EXAS…
BREAKING: Abbott completes $20B senior notes offering to fund the Exact Sciences takeover — $ABT $EXAS 🚨💰 #BREAKING #Mergers #Biotech #FinTwit ALERT:…
Abbott ($ABT) filed an 8-K on Feb 26, 2026 — added Exhibit 1.1 (Pricing Agreement) and XBRL cover page.
Abbott ($ABT) filed an 8-K on Feb 26, 2026 — added Exhibit 1.1 (Pricing Agreement) and XBRL cover page. Disclosure points to an expected closing of a Notes…
BREAKING: $ABT confirms a $20B senior notes offering to fund the Exact Sciences acquisition 🚨💵 Pricing…
BREAKING: $ABT confirms a $20B senior notes offering to fund the Exact Sciences acquisition 🚨💵 Pricing agreement signed with Morgan Stanley, Barclays,…
Abbott Laboratories filed an 8‑K (Item 9.01) on Jan 22, 2026 — furnished a press release (Exhibit 99.1)…
Abbott Laboratories filed an 8‑K (Item 9.01) on Jan 22, 2026 — furnished a press release (Exhibit 99.1) and an Inline XBRL cover page (Exhibit 104). Review…
Abbott filed Q4 & FY2025 results on Jan 22, 2026 (Exhibit 99.1).
Abbott filed Q4 & FY2025 results on Jan 22, 2026 (Exhibit 99.1). The release emphasizes non‑GAAP "net earnings excluding specified items" to show underlying…